mSMART Guidelines Influence Global Multiple Myeloma Care with Updated, Risk-Based Protocols

The Stratification for Myeloma and Risk-Adapted Therapy (mSMART) guidelines, developed to provide clear and effective treatment protocols for multiple myeloma, were introduced due to the lack of structured treatment approaches before 2007. These guidelines have significantly influenced myeloma treatment worldwide. Updated continuously to reflect the latest research and treatments, mSMART offers straightforward, accessible recommendations on managing various stages of multiple myeloma, emphasizing individualized treatment based on risk assessment.

The mSMART guidelines have been well received globally, becoming a primary reference in the myeloma community and facilitating improved treatment outcomes. They incorporate advances in treatment options, such as new drugs and therapies, ensuring that recommendations remain cutting-edge. Furthermore, the guidelines are intended not only to guide healthcare providers but also to empower patients who frequently consult the mSMART website and bring these guidelines to their physicians’ attention. This approach helps in standardizing care and closing the gap in treatment outcomes between patients classified as low-risk and high-risk.

Reference: mSMART: A clear and simple guide for treating patients with multiple myeloma. Mayo Clinic. Accessed June 5, 2024. https://www.mayoclinic.org/medical-professionals/cancer/news/msmart-a-clear-and-simple-guide-for-treating-patients-with-multiple-myeloma/mqc-20506750